STML Stemline Therapeutics, Inc.

8.35
+0.10  (1%)
Previous Close 8.25
Open 8.35
Price To book 2.07
Market Cap 195.19M
Shares 23,376,000
Volume 98,453
Short Ratio 3.69
Av. Daily Volume 230,890

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
High Risk Myeloproliferative Neoplasms
Phase 2 enrollment completed - noted March 23, 2017. Update on patients enrolled in Stages 1 and 2 due at EHA June 23, 2017 with top-line data from Stage 3 due 2H 2017.
SL-401
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) cancer
Phase 2 preliminary data released November 2016.
SL-701
Second line glioblastoma (GBM) cancer
Phase 2 ongoing. ASH oral presentation - December 2016.
SL-401
Cancer- adult relapsed or refractory acute myeloid leukemia (AML)

Latest News

  1. Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association (EHA) Meeting
  2. Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc.
  3. Stemline Therapeutics reports 1Q loss
  4. Stemline Therapeutics Reports First Quarter 2017 Financial Results
  5. J&W Investigates Investment Technology Group (ITG) and Stemline Therapeutics (STML); Should Officers and Directors be Responsible for Alleged Harm to the Company?
  6. Stemline Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
  7. DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
  8. FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017
  9. DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. - Lead Plaintiff Deadline of April 4, 2017 - STML
  10. STEMLINE 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Stemline Therapeutics, Inc. – (STML)
  11. UPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
  12. STML UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Stemline Therapeutics, Inc. and a Lead Plaintiff Deadline of April 4, 2017
  13. DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  14. April 4 Deadline Alert: Law Offices of Howard G. Smith Reminds Stemline Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline
  15. APRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  16. Deadline Alert: GPM Reminds Investors of the April 4 Deadline in the Class Action Lawsuit Against Stemline Therapeutics, Inc.
  17. DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
  18. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) & Lead Plaintiff Deadline: April 4, 2017
  19. EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
  20. DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Stemline Therapeutics, Inc. To Contact The Firm